GlassScriptPhysician profile
Nicholas R Idle
NPI 1467738005
$4,059.87
in general payments reported to CMS, 2019-2025
25 companies · $2,352 in 2025
The $2,352 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $262 · 2022: $146 · 2023: $560 · 2024: $740 · 2025: $2,352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,491 · Education: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,490.74 |
| Education | $160.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $751.56 | 2024-2025 | Tremfya |
| Medtronic, INC. | $453.21 | 2021-2025 | Hawkone, Concertotm |
| Sun Pharmaceutical Industries INC. | $415.91 | 2024-2025 | |
| Abbvie INC. | $388.60 | 2024-2025 | |
| Philips North America LLC | $295.57 | 2023 | |
| Ucb, INC. | $256.04 | 2024-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $196.21 | 2024-2025 | Dupixent, Libtayo |
| Organogenesis INC. | $159.00 | 2024-2025 | Cygnus Dual, Via Matrix |
| Organon LLC | $158.14 | 2025 | Vtama |
| Galderma Laboratories, L.P. | $142.63 | 2025 | Nemluvio |
| Amgen INC. | $127.59 | 2024-2025 | Otezla, Otezla |
| Pfizer INC. | $126.19 | 2024-2025 | |
| Inari Medical, INC. | $123.59 | 2021 | |
| Boston Scientific Corporation | $122.87 | 2021 | |
| Lilly USA, LLC | $70.07 | 2024-2025 | Ebglyss, Taltz |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $54.35 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
| Novartis Pharmaceuticals Corporation | $46.25 | 2024-2025 | |
| Genzyme Corporation | $45.17 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.75 | 2025 | Spevigo |
| Edwards Lifesciences Corporation | $23.38 | 2022 | |
| Arcutis Biotherapeutics, INC. | $16.78 | 2025 | Zoryve |
| Leo Pharma INC. | $16.11 | 2024 | Adbry |
| Dermavant Sciences, INC. | $15.35 | 2024 | Vtama |
| Genentech USA, INC. | $15.25 | 2024 | Xolair |
| Incyte Corporation | $14.30 | 2025 | Opzelura |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Idle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.